Frontiers in Public Health (Jan 2024)

Prevalence of depressive symptoms and correlates among individuals who self-reported SARS-CoV-2 infection after optimizing the COVID-19 response in China

  • Liangjia Wei,
  • Jiao Qin,
  • Zhifeng Lin,
  • Xinju Huang,
  • Jinfeng He,
  • Dee Yu,
  • Fei Zhang,
  • Sisi Li,
  • Ping Cen,
  • Mu Li,
  • Tong Luo,
  • Rongjing Zhang,
  • Shanmei Zhong,
  • Cai Qin,
  • Zeyu Li,
  • Yuan Yang,
  • Huiqi Pan,
  • Mengdi Zhao,
  • Xiaoqiong Wu,
  • Junjun Jiang,
  • Junjun Jiang,
  • Hao Liang,
  • Hao Liang,
  • Li Ye,
  • Li Ye,
  • Bingyu Liang,
  • Bingyu Liang

DOI
https://doi.org/10.3389/fpubh.2023.1268799
Journal volume & issue
Vol. 11

Abstract

Read online

BackgroundThe burden of depression symptoms has increased among individuals infected with SARS-CoV-2 during COVID-19 pandemic. However, the prevalence and associated factors of depressive symptoms among individuals infected with SARS-CoV-2 remain uncertain after optimizing the COVID-19 response in China.MethodsAn online cross-sectional survey was conducted among the public from January 6 to 30, 2023, using a convenience sampling method. Sociodemographic and COVID-19 pandemic-related factors were collected. The depression symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9). Logistic regression analysis was performed to explore the associated factors with depressive symptoms.ResultsA total of 2,726 participants completed the survey. The prevalence of depression symptoms was 35.3%. About 58% of the participants reported experiencing insufficient drug supply. More than 40% of participants reported that they had missed healthcare appointments or delayed treatment. One-third of participants responded experiencing a shortage of healthcare staff and a long waiting time during medical treatment. Logistic regression analysis revealed several factors that were associated with depression symptoms, including sleep difficulties (OR, 2.84; 95% CI, 2.34–3.44), chronic diseases (OR, 2.15; 95% CI, 1.64–2.82), inpatient treatment for COVID-19 (OR, 3.24; 95% CI, 2.19–4.77), with COVID-19 symptoms more than 13 days (OR, 1.30, 95% CI 1.04–1.63), re-infection with SARS-CoV-2 (OR, 1.52; 95% CI, 1.07–2.15), and the increased in demand for healthcare services (OR, 1.32; 95% CI, 1.08–1.61).ConclusionThis study reveals a moderate prevalence of depression symptoms among individuals infected with SARS-CoV-2. The findings underscore the importance of continued focus on depressive symptoms among vulnerable individuals, including those with sleeping difficulties, chronic diseases, and inpatient treatment for COVID-19. It is necessary to provide mental health services and psychological interventions for these vulnerable groups during the COVID-19 epidemic.

Keywords